PEPGUIDE.net
Research-profile comparison

BPC-157 vs TB-500: Research Comparison

Compare the evidence framing, proposed mechanisms, regulatory context, and research limitations in PepGuide's BPC-157 and TB-500 profiles.

Comparison page updated July 12, 2026
This page reuses reviewed summaries from the two underlying profiles. It is not a treatment comparison, dosing recommendation, or statement that the compounds have equivalent evidence.

BPC-157

Mostly preclinical/anecdotal; Major anti-doping and regulatory caution

BPC-157 is one of the most widely discussed “repair peptides” in wellness and online peptide communities. The repair story is plausible because the molecule has strong preclinical data in tendon, ligament, muscle, vascular, and gastrointestinal injury models. The limitation is just as important: popularity, animal data, and community experience are not the same as validated human clinical protocols.

The strongest evidence is preclinical. There is now limited human safety/context data, including a very small IV safety pilot in two healthy adults, but there are still no large completed human randomized trials proving that BPC-157 heals tendon, ligament, gut, or post-surgical injuries in routine clinical use.

Full research profileLive prices

TB-500

Product-identity problem; Preclinical wound-healing rationale

TB-500 is commonly marketed as a tissue-repair peptide related to thymosin beta-4, but the name is not precise. In FDA compounding safety-risk language, TB-500 refers to the thymosin beta-4 fragment LKKTETQ. Full-length thymosin beta-4/Tβ4 is a different 43-amino-acid peptide.

Full-length Tβ4 has broader wound, corneal, inflammatory, and cardiac research context. That evidence should not be automatically transferred to TB-500/LKKTETQ or to vendor-labeled TB-500 vials. Verify sequence identity first.

Full research profileLive prices